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2Abstract28
Background: The effect of statins on plasma concentrations of vascular endothelial growth factor (VEGF),29
the main angiogenic growth factor with pro-inflammatory and atherogenic properties, is controversial. A30
systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to obtain a31
conclusive result in humans.32
Methods: PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases were searched to33
identify RCTs investigating the impact of statins on plasma VEGF concentrations. A random-effects model34
and the generic inverse variance method were used for quantitative data synthesis. Meta-regression,35
sensitivity analysis and publication bias assessments were performed using standard methods.36
Results: Eight RCTs examining the effects of statins on plasma VEGF concentrations were included. Meta-37
analysis suggested a significant reduction of plasma VEGF levels following statin therapy (weighed mean38
difference: -19.88 pg/mL, 95% CI: -35.87, -3.89, p=0.015). VEGF reductions were observed in the subsets of39
trials with treatment durations ≥4 weeks (-19.54, -37.78, -1.30, p=0.036), LDL-C reductions ≥50mg/dL40
(-28.59, -43.68, -13.50, p<0.001), lipophilic statins (-22.31, -40.65, -3.98, p=0.017), and diseased populations41
(-21.08, -39.97, -2.18, p=0.029), but not in the opposite subsets. Meta-regression also suggested a42
significant association between changes in plasma VEGF levels and LDL-C changes, treatment duration, but43
not molar dose of statins.44
Conclusions: These results suggest a significant reduction in plasma VEGF concentrations following statin45
therapy. This effect depends on duration of treatment, LDL-lowering activity, lipophilicity of statins, and46
health status of studied individuals. Further RCTs are needed to explore if the VEGF reduction is implicated47
in the statin benefits on cardiovascular outcomes.48
49
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3Introduction55
Vascular permeability, vasculogenesis and angiogenesis are regulated by a complex interplay among several56
growth factors and their associated receptors. In this process, vascular endothelial growth factor (VEGF)57
family and its receptors play an essential role [1-2]. The VEGF family consists of different isoforms with58
several subtypes; each isoform performs a different role in the endothelial and vascular physiology and59
pathology, as comprehensively reviewed [1-4]. In particular, VEGF is involved in vascular development,60
integrity, homeostasis, thrombogenicity modulation, recruitment of hematopoietic precursors and61
migration of monocytes and macrophages. The angiogenic, permeability-enhancing and pro-inflammatory62
properties of VEGF determine its role in pathological conditions, such as cancer, ischemia and inflammation63
[1-4]. At a cardiovascular level, VEGF is implicated in the progression of atherosclerosis, instability of64
atherosclerotic plaque through induction of neoangiogenesis inside the plaque, prediction of worse clinical65
outcomes in acute coronary syndromes, and cardiac hypertrophy through a nitric oxide (NO)-dependent66
mechanism [1-7].67
Hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) are known to exert beneficial effects on68
the clinical outcomes of cardiovascular diseases both by their lipid-lowering, anti-inflammatory, antioxidant69
and antithombotic effects and by improving endothelial function, attenuating vascular/myocardial70
remodeling and stabilizing atherosclerotic plaques [8-9]. Alternative additional mechanisms by which71
statins may reduce cardiovascular events beyond their lipid reduction effects may be the modulation of72
angiogenesis by reducing VEGF levels, as suggested by some case-control human studies performed almost73
a decade ago [10-11]. More recently, the effects of different statins on the reduction of VEGF levels have74
been shown [12-19]; however, the results of human studies have not been fully conclusive [20-26]. In75
addition, some experimental in-vitro and animal studies have suggested a statin-induced stimulation of76
VEGF expression after endothelial and vascular injuries [27-32]. Furthermore, there is evidence indicating77
that statins could directly augment circulating endothelial progenitor cells (EPCs) through mechanisms78
independent of VEGF [17,19,21-22,33]. Therefore, at present the role of statins on the VEGF homeostasis is79
very controversial.80
4The aim of the present study was to conduct a systematic review and meta-analysis of randomized81
controlled trials (RCTs) to clarify the effect of statin treatment on plasma concentrations of VEGF in82
humans.83
84
Methods85
Search Strategy86
This study was designed according to the guidelines of the 2009 preferred reporting items for systematic87
reviews and meta-analysis (PRISMA) statement [34]. PubMed-Medline, SCOPUS, Web of Science and88
Google Scholar databases were searched using the following search terms in titles and abstracts (also in89
combination with MESH terms): (atorvastatin OR simvastatin OR rosuvastatin OR fluvastatin OR pravastatin90
OR pitavastatin OR lovastatin OR cerivastatin OR “statin therapy” OR statins) AND (VEGF OR "vascular91
endothelial growth factor” OR VEGF-A). The wild-card term ‘‘*’’ was used to increase the sensitivity of the92
search strategy. No language restriction was used in the literature search. The search was limited to studies93
in humans. The literature was searched from inception to January 08, 2015.94
95
Study Selection96
Original studies were included if they met the following inclusion criteria: (i) being a randomized controlled97
trial with either parallel or cross-over design, (ii) investigating the impact of statin therapy on98
plasma/serum concentrations of VEGF, (iii) treatment duration of at least two weeks, (iv) presentation of99
sufficient information on VEGF concentrations at baseline and at the end of follow-up in each group or100
providing the net change values. Exclusion criteria were (i) non-randomized trials, (ii) lack of an appropriate101
control group for statin therapy, (iii) observational studies with case-control, cross-sectional or cohort102
design, and (iv) lack of sufficient information on baseline or follow-up VEGF concentrations.103
104
Data extraction105
Eligible studies were reviewed and the following data were abstracted: 1) first author's name; 2) year of106
publication; 3) study location; 4) study design; 5) number of participants in the statin and control (in case of107
5randomized design) groups; 5) age, gender and body mass index (BMI) of study participants; 6) baseline108
levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol109
(HDL-C), triglycerides, high-sensitivity C-reactive protein (hs-CRP) and glucose; 7) systolic and diastolic110
blood pressures; and 8) data regarding baseline and follow-up concentrations of VEGF.111
112
Quality assessment113
A systematic assessment of bias in the included studies was performed using the Cochrane criteria [35]. The114
items used for the assessment of each study were as follows: adequacy of sequence generation, allocation115
concealment, blinding, addressing of dropouts (incomplete outcome data), selective outcome reporting,116
and other potential sources of bias. According to the recommendations of the Cochrane Handbook, a117
judgment of “yes” indicated low risk of bias, while “no” indicated high risk of bias. Labeling an item as118
“unclear” indicated an unclear or unknown risk of bias.119
120
Quantitative Data Synthesis121
Meta-analysis was conducted using Comprehensive Meta-Analysis (CMA) V2 software (Biostat, NJ) [36]. Net122
changes in measurements (change scores) were calculated as follows: measure at end of follow-up −123
measure at baseline. For single-arm cross-over trials, net change in plasma concentrations of VEGF were124
calculated by subtracting the value after control intervention from that reported after treatment. Standard125
deviations (SDs) of the mean difference were calculated using the following formula: SD = square root126
[(SDpre-treatment)2 + (SDpost-treatment)2 – (2R × SDpre-treatment × SDpost-treatment)], assuming a correlation coefficient (R)127
= 0.5. Where standard error of the mean (SEM) was only reported, standard deviation (SD) was estimated128
using the following formula: SD = SEM × sqrt (n), where n is the number of subjects.129
A random-effects model (using DerSimonian-Laird method) and the generic inverse variance method were130
used to compensate for the heterogeneity of studies in terms of demographic characteristics of populations131
being studied and also differences in study design and type of statin being studied [37]. Heterogeneity was132
quantitatively assessed using I2 index. Effect sizes were expressed as weighed mean difference (WMD) and133
95% confidence interval (CI). Subgroup analyses were carried out to explore the impact of duration (< 4134
6weeks versus ≥ 4 weeks) of statin therapy and type (lipophilic versus hydrophilic) of statin therapy as well135
as magnitude of reduction in plasma LDL-C concentrations (< 50 mg/dL versus ≥ 50 mg/dL) on plasma VEGF136
alterations. To avoid the problem of double-counting in RCTs with multiple treatment arms and a common137
control group, the number of subjects in the control group was splitted among the required comparisons.138
In order to evaluate the influence of each study on the overall effect size, sensitivity analysis was conducted139
using leave-one-out method, i.e. removing one study each time and repeating the analysis [38-39].140
141
Meta-regression142
Random-effects meta-regression was performed using unrestricted maximum likelihood method to143
evaluate the association between calculated WMD and potential confounders including duration of144
treatment with statins, molar dose of statins, and magnitude of LDL-C reduction by statin therapy.145
146
Publication bias147
Potential publication bias was explored using visual inspection of Begg’s funnel plot asymmetry, and Begg’s148
rank correlation and Egger’s weighted regression tests. Duval & Tweedie “trim and fill” and “fail-safe N”149
methods were used to adjust the analysis for the effects of publication bias [40].150
151
Results152
Flow and characteristics of included studies153
With the initial literature search, 235 articles were found (Figure 1). All these records were screened, and154
219 did not meet the inclusion criteria. The full text of the remaining 16 was carefully assessed for eligibility155
and 8 were selected for the meta-analysis because they satisfied the inclusion criteria. Reasons for rejecting156
the other 8 articles were: lack of measurements of VEGF concentrations, non-interventional design, short (<157
2 weeks) treatment duration, lack of control for statin therapy, and incomplete data on VEGF158
concentrations.159
160
7A total number of 330 subjects were included in the 8 eligible studies, comprising 185 individuals treated161
with statins and 145 individuals treated with placebo; subjects in the only cross-over trial were counted 3-162
times, because they were sequentially treated with 3 different statins (Table 1). Overall, we have evaluated163
8 eligible studies with 10 treatment arms. The largest study had a population size of 65 subjects [15], while164
the smallest study recruited only 12 subjects [18]. Included studies were published between 2006-2014 and165
were conducted in the United States [18], Japan [12-13,15,21-23], Greece [17], and Italy [22]. The following166
statins were used: pravastatin [18,21], atorvastatin [12-13,18,22], rosuvastatin [17-18] and pitavastatin167
[15,23]. The duration of statin therapy was variable, ranging from 14 days [13] to 6 months [12]. Most of168
these randomized trials were placebo-controlled and had a parallel design [12,15,17,21-23], one was a169
single-arm triple crossover trial [18], and one compared aspirin plus statin with aspirin alone, without170
placebo [13]. The inclusion criteria were heterogeneous: healthy subjects [18]; healthy subjects with low171
HDL-cholesterol [21]; chronic smokers with mild hypercholesterolemia [23]; patients with acute coronary172
syndromes [12,15]; subjects undergoing coronary artery bypass grafting [13,22]; and subjects with173
congestive heart failure [17]. The demographic and baseline biochemical parameters of the included174
studies are shown in Table 1.175
176
Risk of bias assessment177
A half of the analyzed studies provided insufficient information about randomization procedures (Table 2).178
Similarly, blinding of participants or researchers was often inadequate, since blinding of the study179
personnel [17] or of the participants [18] was unknown. Furthermore, some study designs did not include a180
placebo arm [13,23], and most authors did not report about missing data. However, all studies appeared to181
be free of selective outcome reporting and of other sources of bias.182
183
Effect of statin therapy on plasma VEGF concentrations184
Meta-analysis of data from 10 RCT arms revealed a significant reduction of plasma VEGF concentrations185
following treatment with statins (WMD: -19.88 pg/mL, 95% CI: -35.87, -3.89, p = 0.015). This effect was186
robust in the sensitivity analysis (Figure 2). In subgroup analysis, VEGF reduction was observed in the187
8subsets of trials with treatment durations ≥ 4 weeks (WMD: -19.54 pg/mL, 95% CI: -37.78, -1.30, p = 0.036),188
and LDL-C reductions ≥ 50 mg/dL (WMD: -28.59 pg/mL, 95% CI: -43.68, -13.50, p < 0.001), but not those189
with treatment durations < 4 weeks (WMD: -53.70 pg/mL, 95% CI: -120.47, 13.07, p = 0.115), and LDL-C190
reductions < 50 mg/dL (WMD: -15.04 pg/mL, 95% CI: -33.08, 3.00, p = 0.102) (Figures 1S and 2S). In191
addition, whilst plasma VEGF concentrations were significantly reduced by lipophilic statins (WMD: -22.31192
pg/mL, 95% CI: -40.65, -3.98, p = 0.017), no significant change was observed in RCTs administering193
hydrophilic statins (WMD: -29.58 pg/mL, 95% CI: -83.03, 23.87, p = 0.278) (Figure 3S). A separate analysis194
was also performed to ascertain the effect size in healthy and diseased population groups. This analysis195
revealed a significant VEGF-lowering effect of statin therapy in the subset of studies in diseased populations196
(WMD: -21.08 pg/mL, 95% CI: -39.97, -2.18, p = 0.029), but not in the subset of studies in healthy197
populations (WMD: -32.26 pg/mL, 95% CI: -74.73, 10.21, p = 0.137) (Figure 4S).198
199
Meta-regression200
Random-effects meta-regression was performed to evaluate the impact of potential moderators on the201
estimated effect size. Consistent with the findings of subgroup analysis, changes in plasma VEGF202
concentrations were dependent to duration of treatment (slope: -1.82; 95% CI: -3.62, -0.02; p = 0.047) and203
magnitude of LDL-C reduction (slope: 0.61; 95% CI: 0.28, 0.94; p = 0.0003) by statins. However, there was204
no significant association between changes in plasma VEGF concentrations and molar dose of statins205
administered (slope: -375.66; 95% CI: -906.54, 155.22; p = 0.165) (Figure 3).206
207
Publication bias208
The funnel plot of standard error versus effect size (mean difference) was slightly asymmetric. Using “trim209
and fill” correction, two potentially missing studies on the right side of funnel plot were imputed leading to210
a corrected effect size that was still significant (WMD: -17.01 pg/mL, 95% CI: -33.02, -1.00) (Figure 4). The211
results of Begg’s rank correlation (Kendall’s Tau with continuity correction = -0.13, Z = 0.54, two-tailed p-212
value = 0.592) and Egger’s linear regression (intercept = -1.39, standard error = 0.67; 95% CI = -2.93, 0.14, t213
= 2.09, df = 8.00, two-tailed p = 0.070) tests excluded the possibility of publication bias in the analysis of214
9statins’ effects on plasma VEGF concentrations. The “fail-safe N” test showed that 35 studies would be215
needed to bring the WMD down to a non-significant (p > 0.05) value.216
217
Discussion218
The results of the present meta-analysis of RCTs showed that statin treatment was associated with a219
significant reduction in circulating VEFG concentrations. This effect was greater with lipophilic statins and in220
patients with cardiac diseases, and found to be associated with treatment duration and LDL-lowering effect221
of statins.222
At present, the potential implication of the VEGF family of growth factors in human cardiovascular health is223
highly controversial. Both vasculogenesis, the in-situ formation of blood vessels from migrated EPCs224
differentiating into endothelial cells, and angiogenesis, the sprouting of new capillaries by migrating225
endothelial cells extending pre-existing vasculature, are implicated in adult neovascularization and both are226
stimulated by VEGF [41].227
Therefore, VEGF has been proposed as a potential therapeutic strategy for neovascularization in patients228
with ischemic heart disease [41-42]. However, the balance between hazards and benefits of VEGF is229
delicate [42]: VEGF-mediated neovascularization and microvascular permeability enhancement; its pro-230
inflammatory effects have been implicated in the exacerbation and progression of atherosclerotic plaque231
deposition, restenosis and negative remodeling following injury [1-7,42-43]; clinical trials with VEGF-A have232
not yielded the expected results [44-45]. To complicate matters, the role of circulating VEGF concentrations233
might be questioned since either the expression of VEGF in smooth muscle cells and atherosclerotic vessels234
seems implicated in the progression of atherosclerotic lesions, or elevated VEFG levels may be a surrogate235
marker of myocardial injury rather than the cause [5,12,46].236
However, there seems to be a gradual increase in VEGF concentrations by worsening of atherosclerosis237
[10]; increased circulating levels of VEGF have been correlated with adverse prognosis in acute coronary238
syndromes [7]; an increasing number of studies reported a major contribution for VEGF to plaque239
development and progression, and to calcification processes [5-7,43,47-48]. Finally, inhibitors of VEGF240
receptors can reduce arteriosclerosis induced by abdominal aorta transplantation in animals [49].241
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Statins have several pleiotropic beneficial properties that are important for the treatment of micro- and242
macro-vascular diseases [8-9]. Repair of the damaged endothelial surface of atherosclerotic lesions may243
occur as the result of adjacent cell migration or the mobilization of circulating EPCs derived from bone244
marrow. Statins accelerate re-endothelialization by increasing EPC proliferation, an effect that is245
independent of the putative lipid-lowering activity [9]. Modulation of VEGF, one of the key growth factors246
involved in angiogenesis, is another potential mechanism through which statins may improve endothelial247
function [8,10-32]. Available data about this latter mechanism are highly controversial. Our meta-analysis248
suggested a significant reduction of plasma VEGF concentrations by statins in RCTs while, in experimental249
settings, statins have been reported to induce the release of VEGF from injured endothelium and vascular250
surface [27-32]. However, the results of in-vitro or animal studies are difficult to translate into clinical251
practice [8].252
Several potential mechanisms may account for the VEGF-lowering effects of statins, including increased253
activity of the VEGF receptor Fms-like tyrosine kinase 1, resulting in a decrease in the free VEGF levels [12];254
inhibition of factors that up-regulate VEGF expression, such as the transcription factors sterol regulatory255
element-binding proteins (SREBPs), nuclear factor-kappa B (NF-κB) and hypoxia-inducible factor (HIF),256
reactive oxygen species, and pro-inflammatory cytokines [8,11,14,50-52]; suppression of apolipoprotein257
CIII-induced vascular endothelial activation and inflammation [53]; and reduction of LDL-C and oxidized LDL258
with subsequent down-regulation of VEGF expression [11].259
Our subgroup analysis revealed different effects according to the LDL-lowering effect, duration of260
treatment, lipophilicity of statins and basic condition of populations studied. A greater reduction of VEGF261
levels by statins was observed in studies that employed lipophilic statins [11-14,16,19], recruited subjects at262
a high risk of cardiovascular disease, and had longer duration of treatment [10-12,14,16].263
Lipophilic statins (such as atorvastatin, simvastatin, lovastatin, fluvastatin) can be passively diffused264
through the lipid bilayer of the cellular membrane and can therefore be up-taken by a larger number of265
cells compared with hydrophilic statin (such as rosuvastatin, pravastatin). Accordingly, apoptosis and266
reversion of neointimal thickening in vascular smooth muscle cells are induced by the lipophilic statins, but267
not by pravastatin [8]. Furthermore, lipophilic statins beneficially impact on markers of endothelial268
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dysfunction and oxidative stress [53-55], and rosuvastatin was shown to be less effective than simvastatin269
in improving endothelium-dependent vasodilatation, despite its powerful lipid-lowering action [56]. It270
appears that at equipotent LDL-C lowering effects of lipophilic and hydrophilic statins, the former can exert271
more pronounced effects on endothelial dysfunction [53,55-56]. Intriguingly, simvastatin exerts protective272
effects during acute ischemia in the lipophilic (but not hydrophilic) form [57]. It was therefore hypothesized273
that lipophilic statins may affect endothelial dysfunction by different pleiotropic mechanisms unshared274
with other statins, and possess stronger lipid-independent effects [53-54,58]. A debate about the clinical275
impact of statin lipophilicity exists [54,59], but further investigations are needed, before lipophilicity is276
considered in the choice of statins.277
Pitavastatin has a different metabolism [60] and its role on vascular protection is less defined at present. Its278
effects on plasma VEGF levels are even more controversial: either reduction [15], no change [23] or an279
increase [25] have been reported. This suggests that rather than a class effect, the impact of statins on280
plasma VEGF levels may depend on the specific molecular structure.281
A significant VEGF-lowering effect of statin therapy in the subset of studies performed in diseased cohorts282
was evident when compared to the subset of healthy individuals; differences in baseline VEGF283
concentrations and the more than 2-fold higher number of individuals in the former subset might explain284
the lower 95%CI values found in the patients with cardiac diseases.285
Finally, differences in the cholesterol-lowering efficacy of statins may be another factor that could be286
potentially responsible for the controversial results of literature. We found that greater LDL-C reductions287
were associated with significant VEGF reductions in the RCTs evaluated. Overall, studies with ≥ 50 mg/dL288
reductions in plasma LDL-C concentrations were associated with a greater decrease in VEGF concentrations289
[11-12,14-15,18] compared with studies with a lower decrease in LDL-C concentrations [21-23]. This290
finding suggests that the hypocholesterolemic effect of statins might affect the VEGF-lowering effect of291
these drugs. Indeed, the excess of circulating lipids is an important independent cause of endothelial292
dysfunction, a condition known as lipotoxicity [61]. However, we did not observe any associations between293
the effect and molar dose of statins; indeed, the LDL-C lowering activity is dependent not only to the statin294
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dose, but also to the statin type. In addition, doses of different statins are not directly comparable even295
after conversion into molar doses.296
The translational value of the results of this meta-analysis is evidencing a new potential pleiotropic action297
of statin therapy that may be important in the prevention of cardiovascular and non-vascular diseases. In298
this context, the impact of newer lipid-lowering therapies on plasma VEGF concentrations merits299
investigation [62-66].300
301
Strengths and limitations302
To the best of our knowledge, this is the first systematic review and meta-analysis investigating the effect303
of statin therapy on plasma VEGF levels, that could contribute to advancing knowledge and generating new304
studies in the field. However, a number of limitations deserve mentioning. First of all, findings of the305
present meta-analysis do not provide any proof on the relationship between the reduction in VEGF levels306
and improvement of arterial stiffness, atherosclerotic lesions or cardiovascular events in humans. Second,307
the heterogeneity of studies included in the meta-analysis should be considered as another limitation, since308
either patients with mild hypercholesterolemia or patients with chronic or acute coronary artery diseases309
were enrolled in the RCTs included. Part of this inter-study heterogeneity was addressed by choosing a310
random-effects model for meta-analysis. As another limitation, studies included in this analysis were not311
primarily designed to assess the effects of statins on VEGF concentrations or expression. Finally, the312
number of trials included and the number of individual studied in the present meta-analysis was small.313
However, the current pooled population size was sufficient to detect a significant VEGF-lowering effect of314
statins. Nevertheless, additional studies are required to ascertain the impact of each statin type separately,315
and compare the impact of different statins on plasma VEGF levels.316
317
Conclusions318
Findings from the present meta-analysis of RCTs suggested a significant reduction of plasma VEGF319
concentrations following statin therapy. This effect was found to be dependent on the duration of320
treatment, health status of the cohort, LDL-lowering activity, and lipophilicity of statins. However, further321
13
studies are required to ascertain the presence of any dose-response association for the VEGF-lowering322
effect of each statin. Future RCTs are also warranted to explore if reduction of plasma VEGF levels play a323
role in the established effects of statins in reducing cardiovascular outcomes. Finally, the inhibitory effects324
of statins on VEGF may justify the proposed indications of these drugs in the management of other diseases325
that are mechanistically related to augmented angiogenesis, a hypothesis that merits further investigation.326
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Table 1. Demographic characteristics of the included studies.
Study Cimato18,
2014
Higashi21,
2010
Kodama12
, 2006
Nakamur
a13, 2006
Nakamura15,2
008
Spadacci
o22, 2010
Tousoulis
17, 2011
Yoshida23, 2010
Location USA Japan Japan Japan Japan Italy Greece Japan
Design Randomiz
ed cross-
over trial
Randomiz
ed
placebo-
controlle
d trial
Randomiz
ed
placebo-
controlle
d trial
Randomiz
ed
double-
blind trial
Randomized
placebo-
controlled
trial
Randomiz
ed
double-
blind
placebo
controlle
d trial
Randomiz
ed
double-
blind
placebo
controlled
trial
Randomized
placebo-
controlled trial
Duration 6 weeks 4 weeks 6 months 14 days 1 month 3 weeks 1 month 4 weeks
Inclusion
criteria
Healthy
subjects
Healthy
subjects
with low
HDL-c
Subjects
within 3-
days after
acute
myocardi
al
infarction
Subjects
undergoin
g
coronary
artery
bypass
grafting
Acute
coronary
syndrome
plus carotid
plaques
Patients
undergoi
ng
elective
coronary
artery
bypass
grafting
Subjects
with
systolic
heart
failure
Chronic smokers
with mild
hypercholesterol
emia
Statins Atorvasta
tin
Pravastati
n
Rosuvasta
tin
Pravastati
n
Atorvasta
tin
Atorvastat
in
Pitavastatin Atorvasta
tin
Rosuvasta
tin
Pitavastatin
Participan
ts
12 Cases 15
Controls
14
Cases 25
Controls
25
Cases 15
Controls
16
Cases 33
Controls 32
Cases 25
Controls
25
Cases 21
Controls
18
Cases 15
Controls 15
Age
(years)
43±13 Cases
46±8
Controls
45±9
Cases
65±2
Controls
63±2
Cases
60±13
Controls
63±8
Cases 60±9
Controls 59±9
Cases
66±8
Controls
65±7
Cases
65±11
Controls
66±11
Cases 40 (3)
Controls 38 (2)
Gender
(M/F)
7/5 Cases
11/4
Controls
11/3
Cases
17/8
Controls
19/6
Cases
15/0
Controls
14/2
Cases 25/8
Controls 23/9
Cases
13/12
Controls
14/11
Cases
19/2
Controls
16/2
Cases 15/0
Controls 15/0
BMI
(kg/m2)
24.9±7.2 Cases
23.5±3.2
Controls
23.8±3.3
Cases
23.2±0.6
Controls
24.5±0.6
NS Cases
25.5±3.0
Controls
25.9±3.0
NS Cases
27.8±4.3
Controla
28.0±5.0
Cases 23.6 (0.8)
Controls 23.0
(0.9)
Smokers
(%)
0 Cases 0
Controls
0
Cases 56
Controls
48
NS Cases 36
Controls 34
Cases 48
Controls
44
Cases 19
Controls
22
Cases 100
Controls 100
Glucose
(mg/dL)
NS Cases
88±17
Controls
91±18
NS NS Cases 123±23
Controls
128±23
NS NS Cases 99 (2)
Controls 95 (2)
Insulin
(pmol/L)
NS Cases
88±17
Controls
91±18
NS NS Cases 54±18
Controls
52±18
NS NS NS
22
Diabetes
(%)
0 Cases 0
Controls
0
Cases 60
Controls
64
Cases 33
Controls
25
Cases 30
Controls 32
Cases 0
Controls
0
Cases 0
Controls 0
Cases 0
Controls 0
Total
cholestero
l (mg/dL)
211±28 Cases
178±13
Controls
175±24
Cases
196±8
Controls
202±8
Cases
190±35
Controls
190±40
Cases 240±21
Controls
238±18
Cases
240±39
Controls
244±27
Cases
223±38
Controls
217±38
Cases 199 (9)
Controls 190 (10)
LDLc
(mg/dL)
136±23 Cases
101±15
Controls
104±18
Cases
120±6
Controls
116±7
NS Cases 164±27
Controls
156±23
NS Cases
147±40
Controls
152±33
Cases 125 (8)
Controls 116 (10)
HDLc
(mg/dL)
54±13 Cases
34±3
Controls
34±5
Cases
46±3
Controls
45±3
NS Cases 43±6
Controls 42±5
Cases
46±15
Controls
46±23
Cases
47±9
Controls
41±9
Cases 51 (3)
Controls 57 (3)
Triglycerid
es (mg/dL)
NS Cases
88±27
Controls
85±40
Cases
133±17
Controls
143±12
NS Cases 165±19
Controls
163±18
Cases
151±80
Controls
159±27
Cases
113;106-
177
Controls
120;80-
148
Cases 151 (24)
Controls 118 (14)
Systolic
blood
pressure
(mmHg)
NS Cases
116±11
Controls
114±11
NS NS NS NS NS Cases 119 (4)
Controls 120 (3)
Diastolic
blood
pressure
(mmHg)
NS Cases
67±7
Controls
68±7
NS NS NS NS NS NS
Hypertensi
on (%)
17 Cases 0
Controls
0
Cases 72
Controls
64
Cases 47
Controls
50
Cases 48
Controls 38
Cases 52
Controls
48
Cases 43
Controls
67
Cases 0
Controls 0
Coronary
artery
diseases
(%)
0 Cases 0
Controls
0
Cases 100
Controls
100
Cases 100
Controls
100
Cases 100
Controls 100
Cases 100
Controls
100
Cases 67
Controls
86
Cases 0
Controls 0
C-reactive
protein
(mg/L)
1.1±1.3 Case
1.0±2.1
Control
1.1±2.0
NS NS Cases 0.6±0.3
Controls
0.7±0.3
NS Cases
2.4;0.9-
4.0
Controls
2.5;1.1-
7.6
Cases 1.8 (0.8)
Controls 1.0 (0.3)
VEGF
(pg/mL)
200 (45) Case
85±12
Controls
86±13
Cases
163±19
Controls
143±10
Cases
84±31
Controls
84±36
Cases 176±35
Controls
175±30
Cases
120±40
Controls
120±26
Cases
313±129
Controls
278±221
Cases 63 (11)
Controls 57 (8)
Data are expressed as: mean ± SD mean (SEM) median; 25th-75th percentiles
Abbreviations: BMI = body mass index; HDLc = HDL cholesterol; LDLc = LDL cholesterol; NS = non stated;
VEGF = Vascular Endothelial Growth Factor
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Table 2. Risk of bias assessment in the studies included in this meta-analysis.
Study Random
sequence
generation
Allocation
concealment
Blinding Incomplete
outcome data
Selective
reporting
Free of
other bias
Nakamura15, 2008 L L L U L L
Yoshida23, 2010 U U H U L L
Cimato18, 2014 L L H L L L
Kodama12, 2006 L L L U L L
Nakamura13, 2006 L L H U L L
Tousoulis17, 2011 U U H U L L
Spadaccio22, 2010 U U L U L L
Higashi21, 2010 U U U L L L
Criteria defined for quality assessment are based on the Cochrane guidelines.
Abbreviations: H, high risk of bias; L low risk of bias; U unclear or unrevealed risk of bias
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Figure legends
Figure 1. Flow chart of the number of studies identified and included into the meta-analysis.
Figure 2. Forest plot displaying weighted mean difference and 95% confidence intervals for the impact of
statin therapy on plasma VEGF concentrations. Lower plot shows leave-one-out sensitivity analysis.
Figure 3.Meta-regression plots of the association between mean changes in plasma VEGF concentrations
with duration of statin therapy, magnitude of LDL-C reduction, and molar dose of statins.
32
Figure 4. Funnel plot displaying publication bias in the studies reporting the impact of statin therapy on
plasma VEGF concentrations. Open diamond represents observed effect size; closed diamond represents
imputed effect size.
Figure legends
Figure 1S. Forest plot displaying weighted mean difference and 95% confidence intervals for the impact of
statin therapy on plasma VEGF concentrations in trials with treatment durations of < 4 weeks (upper plot)
and≥ 4 weeks (lower plot).
Figure 2S. Forest plot displaying weighted mean difference and 95% confidence intervals for the impact of
statin therapy on plasma VEGF concentrations in trials with LDL-cholesterol reductions < 50 mg/dL (upper
plot) and ≥ 50 mg/dL (lower plot).
Figure 3S. Forest plot displaying weighted mean difference and 95% confidence intervals for the impact of
statin therapy on plasma VEGF concentrations in trials with lipophilic (upper plot) and hydrophilic statins
(lower plot).
Figure 4S. Forest plot displaying weighted mean difference and 95% confidence intervals for the impact of
statin therapy on plasma VEGF concentrations in trials with diseased (upper plot) and heathy populations
(lower plot).
